Antimicrobial Susceptibility Testing Market
Antimicrobial Susceptibility Testing Market to Reach $5.99 Billion by 2028
[London, United Kingdom] – [1st June 2023] – The global antimicrobial susceptibility testing market is expected to reach $5.99 billion by 2030, according to a new report byPharmanucleus. The market is projected to grow at a CAGR of 6.4% from 2023 to 2030.
Antimicrobial susceptibility testing (AST) is a laboratory procedure used to determine the effectiveness of antimicrobial agents against a specific microbe. AST is used to guide the selection of appropriate antimicrobial therapy for patients with infectious diseases.
The growth of the global AST market is being driven by a number of factors, including the increasing prevalence of infectious diseases, the rising incidence of multidrug-resistant (MDR) infections, and the increasing demand for personalized medicine.
The global AST market is segmented by product type, method, application, end user, and region. By product type, the market is segmented into manual, automated, and consumables. The automated segment is expected to be the fastest-growing segment during the forecast period. This is due to the increasing demand for accurate and rapid AST results, which can be achieved using automated systems.
By method, the market is segmented into diffusion, dilution, and genotyping. The diffusion method is the most commonly used method for AST. However, the dilution method is gaining popularity due to its increased accuracy and sensitivity.
By application, the market is segmented into clinical diagnostics and research. The clinical diagnostics segment is the largest segment of the market. This is due to the increasing demand for AST in hospitals and other healthcare settings.
By end user, the market is segmented into hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions. The hospitals segment is the largest segment of the market. This is due to the increasing demand for AST in hospitals to guide the selection of appropriate antimicrobial therapy for patients with infectious diseases.
The Asia Pacific region is expected to be the fastest-growing region during the forecast period. This is due to the increasing prevalence of infectious diseases, the rising incidence of MDR infections, and the increasing government focus on improving the healthcare infrastructure in the region.
For more information about the report and to request a sample copy, please visit
Contact Us:
John.M
Business Consultant
john.m@pharmanucleus.com
Support: +44 (0)20 8470 4967
https://www.pharmanucleus.com/
About Pharmanucleus
Pharma Nucleus is a market research company that provides clients access to custom, syndicated reports and consulting on one platform. As a company with rich knowledge in analysis and research across healthcare domains, such as pharma, medical device and biotechnology. Insights derived from Pharma Nucleus help life sciences and other healthcare organizations accelerate the launch, development, and dissemination of life-saving therapies, navigate significant attention with key opinion leaders, and help ensure equitable access to healthcare services.